IMOCA: Percutaneous Autologous Bone-marrow Grafting for Open Tibial Shaft Fracture
Study Details
Study Description
Brief Summary
The treatment of open tibial shaft fracture is often complicated by delayed union or non-union. The objective of this study is to evaluate the efficacy of autologous concentrated bone-marrow to accelerate healing of open tibial shaft fractures and to reduce the need for secondary intervention.
In a prospective, randomized, controlled, single-blind study, 186 patients with an open tibial will be randomized to receive either the standard of care (fixation by nail or external fixator and routine soft-tissue management), or the standard of care with percutaneous injection, one month after fracture, of autologous concentrated bone-marrow. Randomization will be stratified by severity of the open wound. The primary outcome measure will be the proportion of patients requiring secondary intervention because of delayed union or nonunion within twelve months post-fracture.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This study will be conducted at 13 University Hospitals in France. The protocol has been approved by the institutional review board. After written informed consent, patients will be randomized, in the days after the fracture in 2 groups of 93 patients : 1) the control group (standard of care only: fixation by nail or external fixator and routine soft-tissue management) and 2) the study group (standard of care with percutaneous injection, one month after fracture, of autologous concentrated bone-marrow). Randomization will be stratified by severity of the open wound and by center. For the wound, strata A comprise Gustilo-Anderson types I, II and III-A and strata B, type III-B.
For the study group, the injection is scheduled at 1 month ± 5 days after the fracture. The techniques have been described by Hernigou (J Bone Joint Surg Am, 2006; 88(sup 1 part 2): 322-327). There are 3 steps: marrow aspiration (300 - 500 g) from iliac crest under general anesthesia, centrifugation in cell therapy unit to obtain a concentrated buffy coat of about 50 ml containing progenitor cells and other mononuclear cells, percutaneous injection in the fracture site of 20-30 ml of the buffy coat under fluoroscopy control.
Apart from the injection, the standard of care is the same for the 2 groups. Patients will be followed for 12 months, with assessments at 1, 2, 3, 6, 9 and 12 months.
All analysis will be based on the intent to treat the population. The primary outcome measure will be the proportion of patients requiring secondary intervention because of delayed union or nonunion within twelve months post fracture. An independent panel of surgeons will evaluate all secondary procedure with the potential of promoting fracture-healing.
An independent evaluation of fracture union will be conducted by a radiology panel blinded to treatment allocation and all other patient data.
An outcome will be considered to be successful when the fracture heal, according to the investigator, without secondary intervention and is radiographically united during patient follow-up.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Control in arm fields Standard treatment Intervention no'Osteosynthesis' |
Procedure: Osteosynthesis
Nail or external fixator Intervention 'Osteosynthesis'
|
| Experimental: IMOCA Intervention 'Osteosynthesis' Percutaneous autologous bone-marrow grafting - surgical technique (ref: Hernigou Ph et al J Bone Joint Surg Am ,2006; 88 (sup 1 part 2): 322-327 |
Procedure: Osteosynthesis
Nail or external fixator Intervention 'Osteosynthesis'
|
Outcome Measures
Primary Outcome Measures
- Proportion of patients requiring secondary intervention because of delayed union or nonunion within twelve month post fracture. [one year]
Secondary Outcome Measures
- Relation between the number of the progenitor available injected with concentrated bone marrow aspirated and the rate of bone union. [one year]
- Comparison of the rate of complications between the 2 groups. [one year]
- Economic impact study. [one year]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 17 years or more
-
Open tibial shaft fracture with Gustilo-Anderson type I, II, III A or B
-
Written informed consent
-
Affiliated to French Social Security
Exclusion Criteria:
-
Circumferential bone loss
-
Vascular or nerve injury
-
Injury, other than tibial fracture, interfering with weight bearing
-
Infection (skin, soft-tissue or bone)
-
Disease or treatment interfering with bone union: head injury with coma, pathologic fracture
-
Medical history on iliac wing contraindicating bone-marrow aspiration
-
Corticoid or immunosuppressive therapy more than one week
-
Pregnancy at the day of inclusion in study
-
History of positive serology for HIV1+2, HBs, HCV
-
Adult in the care of a guardian
-
Impossibility to meet at the appointments for the follow-up
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UH Angers | Angers | France | 49933 | |
| 2 | UH Besançon Jean Minjoz | Besancon | France | 25030 | |
| 3 | UH Brest Cavale Blanche | Brest | France | 29200 | |
| 4 | UH Clermont Ferrand Gabriel Montpied | Clermont Ferrand | France | 63 000 | |
| 5 | UH Grenoble Michallon Hospital | Grenoble | France | 38043 | |
| 6 | UH Grenoble South Hospital | Grenoble | France | 38434 | |
| 7 | UH Nancy Central Hospital | Nancy | France | 54000 | |
| 8 | UH Nantes Hôtel Dieu | Nantes | France | 44 | |
| 9 | UH Pitié Salpétrière AH HP | Paris | France | 75013 | |
| 10 | UH Tours CHRU Trousseau | Tours | France | 37 044 | |
| 11 | UHTOURS | Tours | France |
Sponsors and Collaborators
- University Hospital, Tours
Investigators
- Principal Investigator: Philippe Rosset, Pr, Service d'orthopédie II - CHRU de Tours
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PHRN/06/PR/IMOCA
- ID RCB 2007 - A00032 - 51